RE
INO icon

RBC Europe’s Inovio Pharmaceuticals INO Stock Holding History

RBC Europe’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-109
Closed -$9.39K – 873
2021
Q3 		$9.39K Sell
109
-138
-56% -$13.8K ﹤0.01% 951
2021
Q2 		$27.5K Hold
247
– – ﹤0.01% 737
2021
Q1 		$27.5K Buy
247
+138
+127% +$18.1K ﹤0.01% 685
2020
Q4 		$11.6K Sell
109
-16
-13% -$2.13K ﹤0.01% 849
2020
Q3 		$17.4K Sell
125
-400
-76% -$83.4K ﹤0.01% 674
2020
Q2 		$170K Buy
525
+399
+317% +$64.1K 0.01% 263
2020
Q1 		$11.2K Buy
126
+97
+334% +$5.98K ﹤0.01% 680
2019
Q4 		$1.15K Sell
29
-417
-93% -$12.6K ﹤0.01% 985
2019
Q3 		$11K Sell
446
-1,039
-70% -$31.6K ﹤0.01% 771
2019
Q2 		$52.4K Hold
1,485
– – 0.01% 439
2019
Q1 		$66.5K Sell
1,485
-3,442
-70% -$173K 0.01% 406
2018
Q4 		$236K Hold
4,927
– – 0.03% 211
2018
Q3 		$329K Hold
4,927
– – 0.04% 194
2018
Q2 		$232K Hold
4,927
– – 0.03% 226
2018
Q1 		$278K Hold
4,927
– – 0.03% 210
2017
Q4 		$244K Hold
4,927
– – 0.03% 229
2017
Q3 		$375K Buy
+4,927
New +$367K 0.05% 178

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RBC Europe's INO Position: Q4 2021 in Review

RBC Europe sold out of Inovio Pharmaceuticals (INO) in Q4 2021, closing a stake of 109 shares — an estimated $9.39K sold.

RBC Europe first reported a position in INO in Q3 2017 and held it in 17 quarters. The position peaked at $375K in Q3 2017. 208 funds tracked by Wall St. Rank hold INO as of Q4 2021.

  • RBC Europe reported no remaining Inovio Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 109 Inovio Pharmaceuticals shares in Q4 2021, an estimated $9.39K.
  • RBC Europe first reported a position in Inovio Pharmaceuticals in Q3 2017 and held it in 17 quarters.
  • RBC Europe's Inovio Pharmaceuticals position peaked at $375K in Q3 2017.
  • 208 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.